ALUNBRIG (brigatinib) is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (aNSCLC) who:5
  • Have previously not been treated with an ALK inhibitor
  • Have been treated with crizotinib
Up to 75% of ALK+ aNSCLC patients will develop brain metastases during their disease.6–8 Patients need a treatment that delivers both intracranial and extracranial efficacy.
ALUNBRIG has been evaluated in a head-to-head, Phase 3, multicentre, open-label study vs crizotinib in ALK TKI-naïve patients with ALK+ aNSCLC (ALTA-1L, N=275). Final analysis of ALTA-1L confirmed that after a median follow-up of 40.4 months, (15.2 months for crizotinib), ALUNBRIG demonstrated superior systemic and intracranial efficacy vs crizotinib in ALK-TKI naïve patients.9
logo-brain-lung

SYSTEMIC AND INTRACRANIAL EFFICACY9

ALUNBRIG provided superior systemic and intracranial efficacy vs crizotinib9
  • Halved the risk of disease progression or death vs crizotinib in the ITT population
    (BIRC-assessed mPFS of 24.0 months with ALUNBRIG vs 11.1 months with crizotinib, HR=0.48, 95% CI: 0.35–0.66; P<0.0001)9
  • Over two-thirds reduction in risk of intracranial disease progression or death in patients with any brain metastases at baseline (BIRC-assessed intracranial mPFS of 24.0 months with ALUNBRIG vs 5.5 months with crizotinib, HR=0.29, 95% CI: 0.17–0.51; P<0.0001)9
schedule

GENERALLY MANAGEABLE TOLERABILITY9

ALUNBRIG has a generally manageable tolerability profile9
pills

CONVENIENT DOSING5

ALUNBRIG comes with a convenient dosing schedule5
  • A first-line treatment for ALK+ aNSCLC that has a single tablet, once-daily dosing regimen at the recommended dose. In circumstances where the dose is modified from the recommended dose, more than one tablet may need to be taken9
  • Please refer to the SmPC for further information about the dosing and administration of ALUNBRIG
    scale

    QUALITY OF LIFE9,10

    ALUNBRIG demonstrated HRQOL benefit vs crizotinib9,10
    • Median time to worsening was 26.7 months for ALUNBRIG vs 8.3 months for crizotinib (HR=0.69, 95% CI: 0.49–0.98; P=0.047)9
    • Median duration of improvement in GHS/QOL was not reached with ALUNBRIG vs 12 months for crizotinib (HR=0.27, 95% CI: 0.14–0.49; P<0.0001)10,a

      aAs reported in the 2nd interim analysis of the ALTA-1L trial (data cut-off June 28, 2019).10 All other results are from the final analysis (data cut-off January 29, 2021).9

      ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; aNSCLC, advanced non-small cell lung cancer; BIRC, blinded independent review committee; CPK, creatine phosphokinase; GHS, global health status; HR, hazard ratio: HRQOL, health-related QOL; ITT, intention-to-treat; mPFS, median progression-free survival; NICE, National Institute of Health and Care Excellence; QOL, quality of life; SMC, Scottish Medicines Consortium; SmPC, Summary of Product Characteristics; TKI, tyrosine kinase inhibitor.

      1. NICE. Brigatinib for ALK-positive advanced non-small cell lung cancer that has not been previously treated with an ALK inhibitor [TA670]. Accessed September 2024; 2. NICE. Brigatinib for treating ALK-positive advanced non-small cell lung cancer after crizotinib [TA571]. Accessed September 2024; 3. SMC Advice. Brigatinib for ALK-positive advanced NSCLC previously not treated with an ALK inhibitor. Accessed September 2024; 4. SMC Advice: Brigatinib for ALK positive advanced NSCLC previously treated with crizotinib. Accessed September 2024; 5. ALUNBRIG Summary of Product Characteristics; 6. Solomon BJ, et al. Lancet Oncol 2018;19:1654–667; 7. Descourt R, et al. Lung Cancer 2019;136:109–114; 8. Huber RM, et al. J Thorac Oncol 2020;15:404–415; 9. Camidge DR, et al. J Thorac Oncol 2021;16:2091–2108; 10. Camidge DR, et al. J Thorac Oncol 2020;38:3592–3603.